Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. A systematic overview. JAMA 2004;292:89-96.
Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST- elevation myocardial infarction. N Engl J Med 2006; 354:1477-88.
Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percu- taneous coronary intervention for ST-elevation myocardial infarction : the international randomised open-label ATOLL trial. Lancet 2011;378:693-703.
Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003;42:1348-56.
Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/ non-Q-wave myocardial infarction TIMI 11B–ESSENCE meta-analysis. Circulation 1999;100:1602-8.
White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment eleva- tion acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J 2006; 152:1042-50.
Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-76.
Mehta RH, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007;50:1742-51.
Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-30.
Brito V, Ciapponi A, Kwong J. Factor Xa inhibitors for acute coronary syndromes. Cochrane Database Syst. Rev 2011;Jan 19(1):CD007038.
Stone GW, McLaurin B|T, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16.
Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007;298:2497-506.
Lincoff AM, Steinhubl SR, Manoukian SV, et al. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing per- cutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. JACC Cardiovasc Interv 2008;1: 639-46.
Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST- segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. J Am Coll Cardiol 2009;53:1021-30.
Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocar- dial infarction. N Engl J Med 2011;365:1980-9.
Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarctions (HORIZONS-AMI): 1-year results of a randomized controlled trial. Lancet 2009;374:1149-59.
Dangas G, Mehran R, Guagliumi G, et al. Role of clopi- dogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (Harmonizing Out- comes with RevascularizatiON and Stents in Acute Myo- cardial Infarction) trial. J Am Coll Cardiol 2009;54: 1436-46.
Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare- metal stents in acute myocardial infarction (HORIZONS- AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204.
Astellas Pharma Inc. Astellas Pharma Inc. discontinues development of darexaban (YM150), an oral direct Factor Xainhibitor. http://www.astellas.com/en/corporate/news/ detail/astellas-pharma-inc-discontinu.html (Accessed 5 January 2012).
Steg PG, Mehta SR, Jukema W, et al. RUBY-1: a ran- domized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011;32:2541-54.
Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndromes. N Engl J Med 2011;365:699-708.
23 .Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9.
Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-12.
Hamm CW, Bassand J-P, Agewall S, et al. ESC Guide- lines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting with- out persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999- 3054.
